NVCR stock forecast
Our latest prediction for Novocure Ltd.'s stock price was made on the June 26, 2017 when the stock price was at 17.45$.
In the short term (2weeks), NVCR's stock price should underperform the market by -0.95%. During that period the price should oscillate between -10.31% and +7.32%.
In the medium term (3months), NVCR's stock price should underperform the market by -6.82%. During that period the price should oscillate between -27.33% and +17.56%.Get email alerts
About Novocure Ltd.
Novocure Ltd. is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
At the moment the company generates 322M USD in revenues.
On its last earning announcement, the company reported a loss of -0.28$ per share.
The book value per share is 1.21$
Three months stock forecastJune 26, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|